Shukra Pharmaceuticals: No Deviation in Utilisation of Preferential Issue Proceeds

Shukra Pharmaceuticals Ltd (now Shukra Medtech Limited) has confirmed no deviation or variation in the utilization of proceeds from its preferential issue of 46,43,000 convertible warrants. The company raised ₹10,46,33,630 (Rupees Ten Crores and Forty-Six Lakhs Thirty-Three Thousand Six Hundred Thirty Only) as 75% of the consideration amount. The funds were raised on September 27, 2026, and July 14, 2026. The utilization was for meeting working capital requirements, providing margin for bank guarantees, and investing in the capital expenditure of subsidiary companies, as per the objects mentioned in the Extra Ordinary General Meeting notice. The statement of deviation, reviewed by the Audit Committee, confirms adherence to the original objects.